Comparative Pharmacology
Head-to-head clinical analysis: DEXCHLORPHENIRAMINE MALEATE versus DIPHENHYDRAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXCHLORPHENIRAMINE MALEATE versus DIPHENHYDRAMINE.
DEXCHLORPHENIRAMINE MALEATE vs Diphenhydramine
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexchlorpheniramine maleate is a histamine H1 receptor antagonist that competitively blocks the effects of histamine at peripheral H1 receptors, reducing symptoms of allergic reactions such as vasodilation, increased vascular permeability, and smooth muscle contraction. It also has anticholinergic and sedative properties.
Inverse agonist at histamine H1 receptors, blocking histamine-mediated effects in blood vessels, respiratory smooth muscle, and GI tract; also anticholinergic by blocking muscarinic receptors and sedative via central H1 receptor antagonism.
2 mg orally every 4-6 hours; maximum 12 mg/day
25-50 mg orally or intramuscularly every 4-6 hours; maximum 300 mg/day. Intravenous administration: 10-50 mg slow IV push (max 25 mg/min).
MODERATE Risk
MODERATE Risk
Clinical Note
moderateDiphenhydramine + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Diphenhydramine."
Clinical Note
moderateDiphenhydramine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluticasone propionate."
Clinical Note
moderateDexchlorpheniramine maleate + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateTerminal elimination half-life is 20-24 hours in healthy adults, allowing once or twice daily dosing. Prolonged in hepatic impairment or elderly.
Terminal elimination half-life 4-8 hours in adults; prolonged in hepatic impairment (up to 20 hours) and elderly.
Primarily renal (approximately 70-80% as unchanged drug and metabolites, mainly glucuronide conjugates); minor biliary/fecal elimination (20-30%).
Primarily renal (90-95% as metabolites, <5% unchanged). Minor biliary/fecal elimination (<5%).
Category C
Category C
Antihistamine
Antihistamine
Diphenhydramine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Diphenhydramine."